Compare Twist Bioscience Corp (TWST) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Financial Select Sector SPDR Fund — how do they compare? Twist Bioscience Corp trades at $165.06 (market cap $10.08B), while Financial Select Sector SPDR Fund trades at $54.44 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Financial Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| TWST | XLF | |
|---|---|---|
Market Cap | $10.08B | $50.06B |
Volume | 4,229,037 | 47,464,120 |
Sector | Health | — |
52-Week High | $205.00 | $58.55 |
52-Week Low | $25.45 | $47.80 |
Typical Hold Time | 27 Days | 104 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
XLF trades at $54.48, up 1.36% with a bearish technical signal from moving averages. The ETF faces headwinds as financial stocks lag the S&P 500 by the widest margin since 1990 despite rising bank profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The outlook remains cautious with technical indicators showing bearish momentum. Rising interest rates could benefit financial sector profitability, but regulatory uncertainty and market underperformance relative to broader indices present near-term risks for investors seeking financial sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
